ARCBEST CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARCBEST CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $1.66B | Feb 23, 2011 |
| FY2010 | Dec 31, 2009 | $1.47B | Feb 23, 2011 |
| FY2010 | Dec 31, 2008 | $1.83B | Feb 23, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.01B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.18B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $4.43B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $5.03B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $3.77B | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $816.41M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $794.98M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $627.37M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $701.40M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $717.42M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $173.96M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $195.43M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $298.21M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $213.52M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $23.91M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $29.40M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $15.88M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $1.90M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($5.55M) | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.31M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $244.43M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $172.62M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $394.53M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $276.98M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $30.25M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $39.78M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $20.43M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $7.82M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | ($11.23M) | Feb 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $34.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $52.40M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $40.80M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $32.80M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $25.60M | Feb 25, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.95M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $285.85M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $322.17M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $470.82M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $323.52M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $205.99M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $170.36M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $255.35M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $151.92M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $111.94M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.78M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $223.10M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $219.02M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $148.22M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $58.41M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $43.25M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $90.96M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $43.99M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $65.78M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $68.27M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.45B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.43B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.49B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $2.49B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.11B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.78B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.65B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.54B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.37B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.28B | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.31B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.24B | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $1.15B | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $929.07M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $828.59M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $763.04M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $717.68M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $651.46M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $599.06M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $304.75M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $304.75M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $304.75M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $304.75M | Feb 23, 2024 |
| FY2023 | Dec 31, 2021 | $299.71M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $88.32M | Feb 24, 2023 |
| FY2020 | Dec 31, 2019 | $88.32M | Feb 26, 2021 |
| FY2020 | Dec 31, 2018 | $108.32M | Feb 26, 2021 |
| FY2018 | Dec 31, 2017 | $108.32M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $108.88M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.44B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.27B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.09B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $801.31M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $595.93M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $533.19M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $501.39M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $438.38M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $386.92M | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.03M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $127.44M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $262.23M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $158.26M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $76.62M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $303.95M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $201.91M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $190.19M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $120.77M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $114.28M | Feb 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $189.13M | Mar 3, 2025 |
| FY2024 | Dec 31, 2023 | $228.94M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $264.62M | Feb 23, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 12 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 11 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.97M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $11.30M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $11.54M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $10.83M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $8.14M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $8.16M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $8.19M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $8.24M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $8.26M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $8.32M | Feb 28, 2019 |